https://www.selleckchem.com/pr....oducts/atogepant.htm
One of the challenges developing a live attenuated tetravalent dengue vaccine (TDV) is to overcome the presumed viral interference that may be preventing the induction of a balanced immune response to all 4 serotypes of the dengue virus (DENV1-4). Our live attenuated TDV candidate was developed from wild-type (wt) parental strains (DENV1/03135, DENV2/99345, DENV3/16562, and DENV4/1036, respectively) using a classical host range mutation strategy the same strategy used for the approved live attenuated smallpox, polio, and MMR vaccines.
Like
Comment
Share
